Fulgent Genetics, Inc. FLGT
25.62 USD -0.17 (-0.64%)
Nov 11, 2026, 3:54 PM EST
25.29 Day range 26.73
13.46 52-week range 31.04
- YTD
- -2.49%
- 1 year
- -9.74%
News
benzinga.com Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $25 Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $19 to $25.
seekingalpha.com Fulgent Genetics, Inc. (FLGT) Q3 2026 Earnings Call Transcript Fulgent Genetics, Inc. ( FLGT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Ming Hsieh - Chairman & CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million. TransMedics Group (NASDAQ:TMDX)…
marketbeat.com What Fulgent Genetics (FLGT) Said on Its Q3 Earnings Call Fulgent Genetics NASDAQ: FLGT reported third-quarter revenue of $90.4 million, up 8% from a year earlier, as contributions from Bako Diagnostics and StrataDx and improving collections helped lift…
zacks.com Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Beats Revenue Estimates Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to earnings of $0.14 per share a year ago.
benzinga.com Fulgent Genetics Q3 2026 Earnings Call Transcript Fulgent Genetics (NASDAQ:FLGT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Fulgent Genetics Raises FY2026 Adj EPS Guidance from $(2.35)-$(2.22) to $(1.75)-$(1.65) vs $(2.27) Est; Affirms FY2026 Sales Guidance of $330.000M-$340.000M vs $331.700M Est Fulgent Genetics (NASDAQ:FLGT) raises FY2026 Adj EPS guidance from $(2.35)-$(2.22) to $(1.75)-$(1.65) vs $(2.27) analyst estimate. Affirms FY2026 sales outlook from $330.000 million-$340.000 million…- benzinga.com Fulgent Genetics Q3 Adj. EPS $(0.09) Beats $(0.65) Estimate, Sales $90.412M Beat $86.300M Estimate Fulgent Genetics (NASDAQ:FLGT) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.65) by 86.15 percent. This is a 164.29 percent decrease over earnings of…
businesswire.com Fulgent Reports Third Quarter 2026 Financial Results EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a…
benzinga.com Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $19 Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $15 to $19.
benzinga.com Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analyst estimates for Q3. Other stocks also dip in pre-market.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure…
benzinga.com Fulgent Genetics Lowers FY2026 Adj EPS Guidance from $(1.59) to $(2.35)-$(2.22) vs $(1.55) Est; Lowers FY2026 Sales Guidance from $350.000M to $330.000M-$340.000M vs $351.900M Est Fulgent Genetics (NASDAQ:FLGT) lowers FY2026 Adj EPS guidance from $(1.59) to $(2.35)-$(2.22) vs $(1.55) analyst estimate. Lowers FY2026 sales outlook from $350.000 million to $330.000…
benzinga.com Fulgent Genetics Q2 Adj. EPS $(0.58) Misses $(0.46) Estimate, Sales $85.389M Miss $94.000M Estimate Fulgent Genetics (NASDAQ:FLGT) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.46) by 26.09 percent. This is a 928.57 percent decrease over earnings…- benzinga.com Fulgent Genetics' FID-007 Plus Cetuximab Shows 60% Response Rate And 7.2-Month Median PFS In Phase 2 Head And Neck Cancer Study With Favorable Safety Profile Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today…
benzinga.com Piper Sandler Reiterates Neutral on Fulgent Genetics, Lowers Price Target to $15 Piper Sandler analyst David Westenberg reiterates Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $30 to $15.
benzinga.com Full Transcript: Fulgent Genetics Q1 2026 Earnings Call 
benzinga.com Earnings Scheduled For May 1, 2026 
benzinga.com Nasdaq Down Over 1%; Dell Shares Jump After Q4 Results U.S. stocks down mid-trading, Nasdaq falls 1%. Dow down 1.40%, S&P 500 falls 0.74%. Dell shares up 21% on Q4 earnings.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Dow Dips Over 600 Points; US Producer Prices Increase In January US stocks traded lower, Dow down 600 points. Nasdaq and S&P also fell. Consumer staples up, tech down. Producer prices rose in January.
benzinga.com Fulgent Genetics Sees FY2026 Adj EPS $(1.45) vs $(0.32) Est; Sees Sales $350.000M vs $356.333M Est Fulgent Genetics (NASDAQ:FLGT) is looking for FY2026 Adj EPS of $(1.45) vs $(0.32) analyst estimate. sees sales of $350.000 million vs $356.333 million analyst estimate.
benzinga.com Fulgent Genetics Q4 Earnings Assessment - benzinga.com Fulgent Genetics Q4 Adj. EPS $0.16 Beats $0.03 Estimate, Sales $83.336M Miss $85.381M Estimate Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.03 by 433.33 percent. This is a 300 percent increase over earnings of…
- benzinga.com Earnings Scheduled For February 27, 2026
benzinga.com Earnings Preview: Fulgent Genetics - benzinga.com Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $30 Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $21 to $30.
benzinga.com Fulgent Genetics Raises FY2025 GAAP EPS Guidance from $(2.10) to $(1.70) vs $(1.94) Est Fulgent Genetics (NASDAQ:FLGT) raises FY2025 GAAP EPS guidance from $(2.10) to $(1.70) vs $(1.94) analyst estimate..
benzinga.com Fulgent Genetics Raises FY2025 Adj EPS Guidance from $(0.35) to $0.30 vs $(0.35) Est; Raises FY2025 Sales Guidance from $320.000M to $325.000M vs $320.118M Est Fulgent Genetics (NASDAQ:FLGT) raises FY2025 Adj EPS guidance from $(0.35) to $0.30 vs $(0.35) analyst estimate. Raises FY2025 sales outlook from $320.000 million to $325.000 million vs $320.118…- benzinga.com Fulgent Genetics Q3 Adj. EPS $0.14 Beats $(0.22) Estimate, Sales $84.069M Beat $81.431M Estimate Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $(0.22) by 162.78 percent. This is a 54.84 percent decrease over earnings of…
benzinga.com Earnings Scheduled For November 7, 2025 - benzinga.com Fulgent Genetics's Earnings Outlook
- benzinga.com Fulgent Genetics Reports Phase 2 Cancer Drug Results Ahead Of ESMO 2025 Presentation Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today…
- benzinga.com UBS Upgrades Fulgent Genetics to Buy, Raises Price Target to $30 UBS analyst Lu Li upgrades Fulgent Genetics (NASDAQ:FLGT) from Neutral to Buy and raises the price target from $20 to $30.
- benzinga.com Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $21 Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $23 to $21.
benzinga.com Monolithic Power Systems, Workiva, Interface, AppFolio And Other Big Stocks Moving Higher On Friday - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Fulgent Genetics Raises FY2025 Adj EPS Guidance from $(0.65) to $(0.35) vs $(0.55) Est; Raises FY2025 Sales Guidance from $310.000M to $320.000M vs $310.682M Est Fulgent Genetics (NASDAQ:FLGT) raises FY2025 Adj EPS guidance from $(0.65) to $(0.35) vs $(0.55) analyst estimate. Raises FY2025 sales outlook from $310.000 million to $320.000 million vs $310.682…
- benzinga.com Fulgent Genetics Q2 Adj. EPS $0.07 Beats $(0.18) Estimate, Sales $81.803M Beat $76.205M Estimate Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.18) by 138.25 percent. This is a 53.33 percent decrease over earnings of…
- benzinga.com Earnings Scheduled For August 1, 2025
- benzinga.com Fulgent Genetics Earnings Preview
- benzinga.com Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $23 Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $16 to $23.
- benzinga.com Raymond James Reiterates Outperform on Fulgent Genetics, Raises Price Target to $25 Raymond James analyst Andrew Cooper reiterates Fulgent Genetics (NASDAQ:FLGT) with a Outperform and raises the price target from $24 to $25.
- benzinga.com Fulgent Genetics Affirms FY2025 GAAP EPS Guidance of $(1.95) vs $(1.34) Est Fulgent Genetics (NASDAQ:FLGT) affirms FY2025 GAAP EPS guidance from $(1.95) to $(1.95) vs $(1.34) analyst estimate..
benzinga.com Fulgent Genetics Affirms FY2025 Adj EPS Guidance of $(0.65) vs $(0.66) Est; Affirms FY2025 Sales Guidance of $310.00M vs $310.44M Est Fulgent Genetics (NASDAQ:FLGT) affirms FY2025 Adj EPS guidance from $(0.65) to $(0.65) vs $(0.66) analyst estimate. Affirms FY2025 sales outlook from $310.00 million to $310.00 million vs $310.44…- benzinga.com Fulgent Genetics Q1 Adj. EPS $0.04 Beats $(0.18) Estimate, Sales $73.46M Beat $71.26M Estimate Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.18) by 122.22 percent. This is a 500 percent increase over losses of…
- benzinga.com Earnings Scheduled For May 2, 2025
- benzinga.com A Peek at Fulgent Genetics's Future Earnings
- benzinga.com Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $16 Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $22 to $16.
- benzinga.com Fulgent Genetics Q4 Adj $0.04 Beats $(0.12) Estimate, Sales $76.21M Beat $75.39M Estimate Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.12) by 133.33 percent. This is a 85.71 percent decrease over earnings of…